Ostarine 10 mg, 60 caps

Ostarine (MK-2866) – Enobosarm

Concentration: 100mg/ml – 30ml vial
Molecular Formula: C₁₉H₁₄F₃N₃O₃
Chemical Class: Trifluoromethylbenzenes (SARMs)

Overview

Ostarine, also known as MK-2866 or Enobosarm, is a non-steroidal selective androgen receptor modulator (SARM) originally developed to combat conditions involving muscle wasting, osteoporosis, and age-related muscle degeneration. It belongs to a class of fluoroorganic compounds called trifluoromethylbenzenes, characterized by the presence of a trifluoromethyl group (-CF₃) attached to a benzene ring. This unique chemical structure significantly enhances the compound’s metabolic stability, oral bioavailability, and tissue selectivity, making it one of the most extensively studied SARMs to date.

Mechanism of Action

Ostarine works by selectively binding to androgen receptors in muscle and bone tissue, mimicking the anabolic effects of testosterone without triggering the side effects typically associated with anabolic steroids (e.g., liver toxicity, prostate enlargement, or hormonal suppression). This selectivity allows it to stimulate lean muscle growth, enhance recovery, and support bone density, while minimizing undesired androgenic effects in non-target tissues.

Clinical Research & Trials

Ostarine (Enobosarm) has undergone extensive clinical testing under the direction of pharmaceutical companies, including GTx, Inc., for a variety of conditions. It has progressed through Phases 1, 2, and 3 of clinical trials, focusing on the following therapeutic areas:

• Muscle Atrophy / Sarcopenia
  Demonstrated to increase lean body mass and physical function in patients experiencing muscle wasting due to aging, cancer, or chronic illness.

• Stress Urinary Incontinence (SUI)
  Investigated as a treatment to improve pelvic floor muscle strength, particularly in post-menopausal women.

• Triple-Negative Breast Cancer (TNBC)
  Studied as a hormonal treatment targeting androgen receptors expressed in some forms of TNBC, offering a non-toxic alternative to chemotherapy.

• Non-Small Cell Lung Cancer (NSCLC)
  Explored for use in treating cachexia and maintaining strength during aggressive cancer treatments.

These studies highlight Ostarine’s potential as a next-generation therapeutic agent for muscle preservation and functional improvement in both clinical and performance-focused research settings.

Key Benefits (For Research Purposes Only)

• High selectivity for muscle and bone androgen receptors

• Promotes lean muscle gain and muscular retention

• May support joint health and tendon strength

• Excellent oral bioavailability (no injections needed)

• No conversion to estrogen or DHT

• Minimal hepatotoxicity compared to traditional Anabolics

⚠️ Important Notice

This product is intended strictly for laboratory and research purposes only. It is not approved for human use or consumption. Researchers must adhere to all safety and ethical guidelines during handling and application.

Product Format

• Volume: 30ml

• Concentration: 100mg/ml

• Form: Liquid solution

• Storage: Store in a cool, dry place. Protect from light.